Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Income Before Tax

Profit after all operating and non-operating items but before income tax.

Maze Therapeutics, Inc.NASDAQ: MAZE

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$24.21M, compared with -$32.79M a year earlier. Trailing-twelve-month income before tax was -$122.54M.

Context

  • Income before tax increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$24.21M or moves back toward the trailing-twelve-month quarterly average of -$30.64M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$24.21M+30.0% QoQ
Last fiscal yearDec 2025
-$131.12M-345.5% YoY
LTMMar 2026
-$122.54M-330.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.2%——
1 year-345.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(131.12M) USD
Year-over-year change
-345.5%

Income Before Tax vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -330.7% is the lowest of 8, against a peer median of -30.0%.
  • Income before tax amounts to 612.7% of revenue for MAZE, versus a peer median of 39.8%.
MAZE Competitors
Income Before Tax for MAZE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$35.07M USD-30.0%——
SEPNSepterna, Inc.LTM Sep 2026-$53.06M USD+10.0%—55.1%
ARDXArdelyx, Inc.LTM Mar 2026-$57.94M USD-9.8%—13.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$67.07M USD-110.1%—6.6%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$122.54M USD-330.7%—612.7%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$159.72M USD-80.4%—24.5%
IVAInventiva S.A.FY2025-€342.33M EUR-86.1%—7636.1%
Peer median (excluding MAZE) —-30.0%—39.8%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.